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ABSTRACT
Introduction: The aim of this systematic review is to
assess the efficacy and safety of Chinese herbal
medicine for the treatment of patients with vascular
cognitive impairment but no dementia.
Methods and analysis: We will perform a
comprehensive retrieval in the following electronic
databases: PubMed, Cochrane Library, EMBASE,
CINAHL, Chinese Biomedical Literature Service System
(SinoMed), China National Knowledge Infrastructure
(CNKI), Chinese Scientific Journals Database (VIP),
Wan-fang database and other sources. After screening
the studies, the methodological quality of all included
trials will be assessed according to the risk of bias
instrument provided by the Cochrane Collaboration. A
meta-analysis of randomised controlled trials will be
conducted using RevMan V.5.3 software. Funnel plot
analysis and Egger’s test will be used to assess
publication bias, if possible. The quality of evidence
will be assessed by the GRADE system.
Dissemination: This systematic review will be
disseminated in a peer-reviewed journal and a relevant
conference presentation.
Trial registration number: PROSPERO CRD
42015023682.
INTRODUCTION
As the population ages and survival from vas-
cular disease are improved, cognitive dys-
function and dementia caused by
cerebrovascular disease (CVD) have become
prevalent.1 Recently, vascular cognitive
impairment (VCI) has been introduced to
describe the entire spectrum of cognitive dys-
function—ranging from cognitive impair-
ment without dementia to dementia—
attributable to all forms of CVD.1 2 There are
three subtypes of VCI: VCI no dementia
(VCIND), vascular dementia (VaD) and
mixed VaD and Alzheimer’s disease (AD).3
Among them, VCIND is characterised by
early or mild cognitive impairment due to
cerebrovascular injuries with an insidious
nature.4 It may be considered to be the pro-
dromal stage of VaD,5 with occurrence in
26.9% of patients approximately 3 months
after stroke onset.6 A cohort study which
included 149 participants with VCIND
showed that 46% cases were observed to
develop dementia, and 52% of these cases
died within 5 years.7 Another community-
based, cross-sectional study in China also
reported that the overall prevalence of post-
stroke cognitive impairment (PSCI) was
80.97% (95% CI 77.82% to 84.11%), while
that of non-dementia PSCI (PSCI-ND) and
post-stroke VaD was 48.91% (95% CI 44.91%
to 52.92%) and 32.05% (95% CI 8.32% to
35.79%), respectively.8
Fortunately, VCIND is potentially treatable
and preventable.3 Early diagnosis and appro-
priate interventions may contribute to the
improvement of the prognosis.9 However,
there are limited treatment options to
improve cognition and function in VCI.1
Chinese herbal medicine (CHM), which has
been used for thousands of years in China,
has been considered promising for improv-
ing cognitive function.10 A meta-analysis of
Strengths and limitations of this study
▪ This study is a comprehensive, objective and
normative systematic review on the efficacy and
safety of Chinese herbal medicine for vascular
cognitive impairment in participants without
dementia.
▪ Study screening, data extraction and assessment
of the risk of bias will be conducted independ-
ently by two researchers.
▪ Currently, there is a lack of internationally recog-
nised diagnostic criteria in vascular cognitive
impairment without dementia. Therefore, sub-
group analyses will be carried out to explore any
sources of heterogeneity.
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CHM for VaD showed that there were signiﬁcant bene-
ﬁts associated with CHM groups in terms of effective
rate, Mini-Mental State Examination (MMSE) scores and
Hasegawa Dementia Scale scores at the end of treat-
ment. Furthermore, fewer adverse events occurred in
the treatment group. In the light of this evidence, CHM
appears to be safe and effective for VaD.11 A
meta-analysis which focused on the efﬁcacy and safety of
CHM for VCIND indicated that CHM could improve
patients’ cognitive and behavioural functions compared
to the treatment with Western medicine.12 However, the
information source was limited to Chinese medical data-
bases and there was no ﬂow chart to show the study
screening process. Therefore, we aim to carry out a
more comprehensive and normative systematic review to
provide objective and scientiﬁc evidence on CHM for
the treatment of VCIND.
METHODS AND ANALYSIS
Inclusion and exclusion criteria for study selection
Types of studies
Randomised controlled trials (RCTs) which used CHM
or a combination of CHM and routine pharmacotherapy
as treatment measures will be eligible. Language will be
limited to English and Chinese.
Types of participants
1. No internationally recognised diagnostic criteria cur-
rently exist and no laboratory tests are available for
VCIND diagnosis.13 14 Therefore, this study will
include patients who were diagnosed with VCIND
based on diagnostic criteria used in international
clinical trials15–17 or Chinese expert consensus.18–20
2. The study will include all types of patients regardless
of their age, sex, ethnicity, education or economic
status and whether or not they were outpatients or
inpatients.
3. Patients should have acquired cognitive impairment,
but not meet the diagnostic criteria for any type of
dementia. Furthermore, their cognitive impairment
was judged to have vascular risk factors or CVD
(including clinical features or radiographic features).
Types of interventions
Studies reporting any type of CHM treatment will be
included. CHM could be used alone or combined with
routine pharmacotherapy. Studies where the control
group is different from the pharmacotherapy in the
intervention group will be excluded. Trials in which the
intervention group includes any other Chinese medicine
therapies (eg, acupuncture, moxibustion, massage,
taichi, etc) will be excluded.
Types of comparators
Comparators will include placebo control, no treatment,
routine pharmacotherapy, routine care and other con-
ventional treatments.
Primary outcome assessments
Primary outcome measures for assessment should
include at least one of the internationally recognised
evaluation scales, which refer to one of the following
aspects: cognitive function, activities of daily living,
behavioural and psychological symptoms of dementia
(BPSD) or global evaluation scales (table 1).
Secondary outcome assessments
The secondary outcome assessments will be the inci-
dence and severity of adverse events.
Search methods for identification of studies
Electronic searches
We will perform a comprehensive retrieval for studies
that evaluate the efﬁcacy and safety of CHM in patients
with VCIND in major Chinese and English medical data-
bases including PubMed, Cochrane Library, EMBASE,
CINAHL, Chinese Biomedical Literature Service System
(SinoMed), China National Knowledge Infrastructure
(CNKI), Chinese Scientiﬁc Journals Database (VIP) and
Wan-fang database from their respective inceptions to
July 2015. The following subject terms and key words
Table 1 Summary of primary outcome assessments
Outcome categories Outcome measures
Cognitive function ▸ MMSE (Mini-Mental
Status Examination)
▸ HDS (Hasegawa
Dementia Scale)
▸ ADAS-cog (Alzheimer’s
disease assessment
scale-cognitive)
▸ MoCA (Montreal Cognitive
Assessment)
▸ WMS (Wechsler Memory
Scale)
Activities of daily living ▸ Activities of daily living
▸ ADCS-ADL (Alzheimer
disease cooperative
study-ADL inventory)
▸ FAQ (Functional activity
questionnaire)
Behavioural and
psychological symptoms of
dementia (BPSD)
▸ NPI (neuropsychiatric
inventory)
▸ HAMD (Hamilton
depression scale)
▸ CSDD (Cornell scale for
depression in dementia)
Global evaluation ▸ CDR (clinical dementia
rating)
▸ CIBIC-plus (clinicians’
interview-based
impression of
change-plus)
▸ GDS (global deterioration
scale)
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will be used in the search: (‘vascular cognitive impair-
ment’ OR ‘mild cognitive impairment’ OR ‘post-stroke
cognitive impairment’ OR ‘VCI’) and (‘Medicine,
Chinese Traditional’ OR ‘Drugs, Chinese Herbal’ OR
‘herbal medicine’ OR ‘Chinese traditional medicine’
OR ‘Traditional Chinese medicine’). Chinese transla-
tions of these search terms will be utilised to search the
Chinese databases. The search strategy for PubMed is
given in table 2 and detailed steps are shown in online
supplementary appendix 1.
Other sources
Studies from other sources will also be obtained from
the following sources:
1. Google scholar (http://scholar.google.com) and
Baidu scholar (http://xueshu.baidu.com/);
2. Clinical Trials.gov (http://www.clinical trails.gov) and
Chinese Clinical Trial Registry (http://www.chictr.
org/cn/);
3. The reference lists of the retrieved articles.
Data extraction and quality evaluation
EndNote X6 software will be used to manage the litera-
ture and the process of removing duplications. A data
extraction EXCEL table will be designed which includes
the data on age, sex, duration, education level, lifestyle
(eg, smoking, alcohol consumption), vascular risk
factors (eg, hypertension, hyperlipidaemia, diabetes),
medical comorbidities, concurrent medications (eg,
antiplatelet aggregation drugs, antihypertensive drugs,
hypoglycaemic drugs), randomisation, blinding, inter-
ventions, comparators, outcomes, study dropouts, the
incidence and details of adverse effects. Two researchers
(MF and JL) will extract and double-check the data from
the included articles. Any discrepant data will be
reviewed by discussion with another team member (SL).
The details of the study selection will be shown in a
PRISMA ﬂow chart (ﬁgure 1).
Risk of bias assessment of included studies
The methodological quality of all included trials will be
assessed by a ‘risk of bias assessment tool’ according to the
Cochrane Handbook 5.1 by two independent researchers
(MF and JL). Any different views will be discussed with
another team member (SL). The risk of bias in the
included studies will be evaluated according to the eight
domains: randomisation sequence generation, randomisa-
tion allocation concealment, blinding of participants,
blinding of personnel, blinding of outcome assessors,
incomplete outcome data, selective outcome reporting
and other sources of bias. Since many reports of RCTs
published in Chinese journals lacked an adequate descrip-
tion of randomisation sequence generation and allocation
concealment,21 we will retrieve related protocols in clinical
trials registration websites and contact ﬁrst author/s or cor-
responding author/s through email or telephone for
further details of these two domains.
Strategy for data synthesis and statistical analysis
We will use RevMan V.5.3 software for data analysis. For
continuous data collected using the same measurement
scale, we will calculate weighted mean difference and
95% CIs. For continuous data collected using similar
measurement scales for the same outcome, we will calcu-
late standardised mean differences with 95% CIs. For
dichotomous outcomes, we will use risk ratio with 95%
CI and p values to assess the efﬁcacy and safety of CHM.
A standard χ2 statistic and I2 statistic will be used to test
heterogeneity between groups. Data will be analysed
with a ﬁxed-effect model if no statistical heterogeneity
was observed between subgroups (p≥0.1, I2≤50%). In
the presence of heterogeneity (p<0.1, I2>50%), a
random-effect model will be used and the possible
causes of heterogeneity will be examined.
Dealing with missing data or unclear scale type
We will attempt to contact the authors of included
studies in which there are missing data or unclear
sources of the evaluation scales through email or tele-
phone. For missing data, if we fail to obtain sufﬁcient
data after contacting authors, an intention-to-treat ana-
lysis will be performed if feasible.
Planned subgroup analyses
Where possible, we will perform subgroup analyses
based on different demographic characteristics or vascu-
lar risk factors, severity of included patients, different
disease durations, diagnostic criteria, intervention type
(CHM or CHM in combination with routine pharmaco-
therapy), routes of administration, dosage, preparations
and ingredients of CHM interventions and controls.
Sensitivity analysis
Where feasible, we will carry out sensitivity analyses to
investigate the robustness of the study conclusions, such
as grouping studies by different levels of the methodo-
logical quality.
Table 2 Search strategy used in the PubMed database
No Search terms
1 vascular cognitive impairment
2 mild cognitive impairment
3 post-stroke cognitive impairment
4 VCI
5 or 1–4
6 Medicine, Chinese Traditional
7 Drugs, Chinese Herbal
8 herbal medicine
9 Chinese traditional medicine
10 Traditional Chinese medicine
11 or 6–10
12 5 and 11
This search strategy will be modified as required for other
electronic databases.
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Assessment of publication biases
We will use funnel plots in RevMan V.5.3 and Egger’s
test in Stata 11.0 to detect publication bias if more than
10 studies are included in the meta-analysis.
Assessment of quality of evidence
The Cochrane Collaboration Network GRADE (The
Grading of Recommendations Assessment Development
and Evaluation) will be used to assess the results in this
systematic review. We will create a Summary of Finding
table in http://www.guidelinedevelopment.org/.
Ethics and dissemination
Ethical approval will not be required for this systematic
review because there are no concerns regarding the
patient’s privacy. The results will be disseminated in a
peer-reviewed journal and presented at a relevant
conference.
DISCUSSION
VCIND belongs to the categories of Jianwang, Shanwang,
Daibing in traditional Chinese medicine.22 CHMs have
been cited for treating memory disorders in the classical
herbal literature for many centuries,23 and the results of
preclinical and clinical studies suggest that CHM could
improve cognitive decline.24 25 For example, Ginkgo
biloba extract EGb 761 is the most extensively clinically
tested Chinese herbal-based substance for cognitive
impairment and dementia and meta-analytic evidence
suggests that EGb 761 provides beneﬁt for stabilising or
slowing decline in cognition of people with cognitive
impairment and dementia.26 Huperzine A is another
Chinese herbal derivative which has been authorised for
treating AD and benign memory deﬁcits since 1994 in
China.27 As an alkaloid isolated from the Chinese herb
Huperzia serrata, Huperzine A can selectively inhibit acet-
ylcholinesterase activity and thus facilitate the increase
in acetylcholine level in the brain, thereby improving
cognitive function in patients with dementia.28
Meta-analysis also shows that Huperzine A could signiﬁ-
cantly improve the MMSE and ADL scores of patients
with AD and VD with a good tolerance.28 However,
there is, as yet, no overall assessment of the clinical evi-
dence regarding CHM interventions for VCIND in
evidence-based medicine.
Thus, we plan to conduct this meta-analysis to evaluate
the efﬁcacy and safety of CHM therapies for patients with
VCIND. We hope that this review will provide evidence to
assist clinicians and patients’ decision-making process
when dealing with VCIND. However, no internationally
recognised VCIND diagnostic criteria exist currently. This
will be a potential source of heterogeneity for the
included study population and inﬂuence the extrapola-
tion of conclusion. Therefore, subgroup analyses accord-
ing to the characteristics of VCIND and different
diagnosis criteria will need to be carried out.
Figure 1 Flow diagram of
selection process.
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PRISMA-P (Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols) 2015 checklist29 of
this protocol is presented in online supplementary
Appendix 2.
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